Wave life sciences announces positive update to ongoing phase 1b/2a focus-c9 study driven by potent, durable reductions of poly(gp) with low, single doses of wve-004

Reductions in poly(gp), a key disease biomarker indicating target engagement, observed across all treatment groups after single doses

WVE Ratings Summary

WVE Quant Ranking